UCB Cares

Trials

Studies that name UCB Cares as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:55 UTC. Showing 200 of 236. Open this list on ClinicalTrials.gov

• Ph1
  NCT07849894 · A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.

  UCB Biopharma SRL · completed · Mild to Moderate Psoriasis, Healthy Volunteers · study director
• N/A
  NCT07531511 · SLC6A1-NDD Prospective Longitudinal Natural History Study

  UCB Biopharma SRL · recruiting · SLC6A1 Neurodevelopmental Disorder (NDD), Developmental and Epileptic Encephalopathies (DEE) · study director
• Ph3
  NCT07503444 · A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

  UCB BIOSCIENCES, Inc. · recruiting · Rett Syndrome · study director
• Ph1
  NCT07290036 · A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

  UCB Biopharma SRL · recruiting · Psoriatic Arthritis, Axial Spondyloarthritis · study director
• Ph1
  NCT07286682 · A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants

  UCB Biopharma SRL · active not recruiting · Healthy Participants · study director
• Ph2
  NCT07277660 · A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

  UCB Biopharma SRL · active not recruiting · Atopic Dermatitis · study director
• Ph4
  NCT07246564 · Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

  UCB Biopharma SRL · active not recruiting · Myasthenia Gravis · study director
• Ph1
  NCT07220551 · A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants

  UCB Biopharma SRL · completed · Healthy Volunteers · study director
• Ph3
  NCT07219420 · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

  UCB Biopharma SRL · recruiting · Palmoplantar Pustulosis · study director
• Ph1
  NCT07020988 · A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

  UCB Biopharma SRL · completed · Healthy Participants · study director
• Ph1
  NCT06970301 · A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

  UCB Biopharma SRL · completed · Healthy Study Participants · study director
• Ph1
  NCT06961747 · A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

  UCB Biopharma SRL · recruiting · Healthy Participants · study director
• Ph3
  NCT06921850 · A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

  UCB Biopharma SRL · active not recruiting · Hidradenitis Suppurativa · study director
• Ph1
  NCT06888193 · A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

  UCB Biopharma SRL · recruiting · Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis · study director
• Ph1
  NCT06720714 · A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

  UCB Biopharma SRL · completed · Healthy Participants · study director
• Ph1
  NCT06716879 · A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

  UCB Biopharma SRL · completed · Healthy Participants · study director
• Ph1
  NCT06679413 · A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

  UCB BIOSCIENCES, Inc. · completed · Healthy Study Participants · study director
• Ph3
  NCT06668181 · An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

  UCB Biopharma SRL · recruiting · Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis · study director
• Ph3
  NCT06624228 · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

  UCB Biopharma SRL · completed · Psoriatic Arthritis · study director
• Ph3
  NCT06617325 · A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  UCB Biopharma SRL · recruiting · Systemic Lupus Erythematosus · study director
• N/A
  NCT06590493 · Doxecitine and Doxribtimine-Expanded Access

  UCB BIOSCIENCES, Inc. · available · Thymine Kinase 2 Deficiency · study director
• Ph1
  NCT06555601 · A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy Participants

  UCB Biopharma SRL · terminated · Healthy Participants · study director
• Ph3
  NCT06540144 · An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

  UCB Biopharma SRL · active not recruiting · Generalized Myasthenia Gravis · study director
• Ph1
  NCT06511076 · A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants

  UCB Biopharma SRL · completed · Healthy Volunteers · study director
• Ph3
  NCT06506916 · A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

  UCB Biopharma SRL · active not recruiting · Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis · study director
• Ph3
  NCT06471361 · A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

  UCB Biopharma SRL · completed · Generalized Myasthenia Gravis · study director
• Ph3
  NCT06435312 · An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

  UCB Biopharma SRL · enrolling by invitation · Generalized Myasthenia Gravis · study director
• Ph3
  NCT06425549 · A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

  UCB Biopharma SRL · active not recruiting · Moderate to Severe Plaque Psoriasis · study director
• Ph1
  NCT06312566 · A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants

  UCB Biopharma SRL · completed · Healthy Study Participants · study director
• Ph2/Ph3
  NCT06149559 · A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

  UCB Biopharma SRL · completed · Generalized Myasthenia Gravis · study director
• Ph3
  NCT06118255 · A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

  UCB BIOSCIENCES, Inc. · completed · Dravet Syndrome · study director
• Ph2/Ph3
  NCT06055959 · A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

  UCB Biopharma SRL · recruiting · Generalized Myasthenia Gravis · study director
• Ph2
  NCT06055985 · A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

  UCB Biopharma SRL · completed · Parkinson Disease · study director
• Ph3
  NCT06011733 · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

  UCB Biopharma SRL · completed · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis · study director
• Ph1
  NCT05845645 · A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

  UCB Biopharma SRL · completed · Healthy Study Participants · study director
• Ph3
  NCT05681715 · A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

  UCB Biopharma SRL · completed · Generalized Myasthenia Gravis · study director
• Ph2
  NCT05643794 · A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome

  UCB Biopharma SRL · completed · Fibromyalgia · study director
• Ph1
  NCT05626439 · A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

  UCB Biopharma SRL · completed · Healthy Participants · study director
• Ph2
  NCT05543252 · An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

  UCB Biopharma SRL · terminated · Parkinson's Disease · study director
• Ph3
  NCT05514873 · An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

  UCB Biopharma SRL · completed · Generalized Myasthenia Gravis · study director
• Ph1
  NCT05315947 · A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

  UCB Biopharma SRL · completed · Healthy Study Participants · study director
• Ph1
  NCT05292131 · A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

  UCB Biopharma SRL · completed · Healthy Study Participants · study director
• Ph1/Ph2
  NCT05277571 · A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

  UCB Biopharma SRL · completed · Atopic Dermatitis · study director
• Ph3
  NCT05109234 · A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

  UCB Biopharma SRL · completed · Childhood Absence Epilepsy, Juvenile Absence Epilepsy · study director
• Ph3
  NCT05077904 · A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

  UCB Biopharma SRL · recruiting · Stereotypical Prolonged Seizures · study director
• Ph3
  NCT05076617 · A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

  UCB Biopharma SRL · enrolling by invitation · Stereotypical Prolonged Seizures · study director
• Ph3
  NCT05067335 · A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

  UCB Biopharma SRL · completed · Osteoporosis · study director
• Ph3
  NCT05064878 · A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

  Zogenix, Inc. · active not recruiting · CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm · study director
• Ph3
  NCT05063162 · A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

  UCB Biopharma SRL · active not recruiting · Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) · study director
• Ph1
  NCT05028127 · A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

  UCB Celltech · completed · Healthy Volunteers · study director
• Ph3
  NCT05020249 · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

  UCB Biopharma SRL · completed · Moderate to Severe Plaque Psoriasis · study director
• N/A
  NCT05017818 · A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency

  Zogenix MDS, Inc. · completed · Thymidine Kinase 2 Deficiency · study director
• N/A
  NCT05014724 · CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

  UCB Biopharma SRL · no longer available · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · study director
• Ph3
  NCT04976322 · A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

  UCB Biopharma SRL · enrolling by invitation · Systemic Lupus Erythematosus · study director
• Ph3
  NCT04901195 · A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

  UCB Biopharma SRL · completed · Hidradenitis Suppurativa · study director
• Ph1
  NCT04882540 · A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects

  UCB Biopharma SRL · completed · Healthy Participants · study director
• Ph2
  NCT04875975 · A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

  UCB Biopharma SRL · terminated · Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis · study director
• Ph1
  NCT04875962 · A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

  UCB Biopharma S.P.R.L. · completed · Parkinson's Disease · study director
• Ph1
  NCT04867642 · A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

  UCB Biopharma SRL · completed · Healthy Study Participants, Parkinson's Disease · study director
• Ph2
  NCT04867616 · A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

  UCB Biopharma SRL · completed · Alzheimer's Disease · study director
• Ph1
  NCT04857307 · A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

  UCB Biopharma SRL · completed · Epilepsy · study director
• Ph1
  NCT04828343 · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

  UCB Biopharma SRL · completed · Healthy Study Participants · study director
• Ph1
  NCT04802746 · A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

  UCB Biopharma SRL · completed · Healthy Study Participants, Participants With Mild Asthma · study director
• Ph1
  NCT04782388 · Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants

  UCB Biopharma SRL · completed · Healthy Study Participants · study director
• Ph1
  NCT04740814 · A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

  UCB Biopharma SRL · completed · Rheumatoid Arthritis · study director
• Ph2
  NCT04718896 · A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

  UCB Biopharma SRL · completed · Moderate to Severe Plaque Psoriasis · study director
• Ph3
  NCT04715646 · A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

  UCB Biopharma SRL · recruiting · Epilepsy · study director
• Ph1
  NCT04705350 · A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

  UCB Biopharma SRL · completed · Healthy Study Participants · principal investigator
• Ph3
  NCT04666610 · A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

  UCB Biopharma SRL · completed · Childhood Absence Epilepsy, Juvenile Absence Epilepsy · study director
• Ph1
  NCT04658199 · A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

  UCB Biopharma SRL · active not recruiting · Progressive Supranuclear Palsy · study director
• Ph2
  NCT04658186 · A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

  UCB Biopharma SRL · completed · Early-stage Parkinson's Disease · study director
• Ph3
  NCT04650854 · A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

  UCB Biopharma SRL · completed · Generalized Myasthenia Gravis · study director
• Ph1
  NCT04651153 · A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)

  UCB Biopharma SRL · completed · Parkinson's Disease · study director
• Ph1/Ph2
  NCT04643457 · A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

  UCB Biopharma SRL · completed · Atopic Dermatitis · study director
• Ph3
  NCT04643483 · A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease

  UCB Biopharma SRL · withdrawn · Crohn's Disease · study director
• Ph3
  NCT04627285 · A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

  UCB Biopharma SRL · completed · Epilepsy · study director
• Ph3
  NCT04596995 · A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  UCB Biopharma SRL · terminated · Primary Immune Thrombocytopenia · study director
• Ph3
  NCT04581733 · A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)

  Zogenix MDS, Inc. · withdrawn · Thymidine Kinase 2 Deficiency · study director
• Ph2
  NCT04519645 · A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures

  UCB Biopharma SRL · terminated · Electroencephalographic Neonatal Seizures, Epilepsy · study director
• Ph1
  NCT04444466 · A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants

  UCB Biopharma SRL · terminated · Healthy Study Participants, Chronic Spontaneous Urticaria · study director
• Ph3
  NCT04436640 · A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

  UCB Biopharma SRL · completed · Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa · study director
• Ph1/Ph2
  NCT04393298 · A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

  UCB Biopharma SRL · completed · Advanced Solid Tumors · study director
• Ph1/Ph2
  NCT04335578 · A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury

  UCB Biopharma SRL · terminated · Chronic Allograft Injury · principal investigator
• Ph3
  NCT04294667 · A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  UCB Biopharma SRL · completed · Systemic Lupus Erythematosus · study director
• Ph1
  NCT04283136 · A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil

  UCB Biopharma SRL · withdrawn · Healthy Participants, Epilepsy · study director
• Ph1
  NCT04255862 · A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

  UCB Biopharma SRL · terminated · Healthy Study Participants · study director
• Ph3
  NCT04242446 · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

  UCB Biopharma SRL · completed · Hidradenitis Suppurativa · study director
• Ph3
  NCT04242498 · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

  UCB Biopharma SRL · completed · Hidradenitis Suppurativa · study director
• Ph3
  NCT04225871 · Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

  UCB Biopharma SRL · completed · Generalized Myasthenia Gravis · study director
• Ph3
  NCT04224688 · A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  UCB Biopharma SRL · terminated · Primary Immune Thrombocytopenia · study director
• Ph3
  NCT04200456 · A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  UCB Biopharma SRL · terminated · Primary Immune Thrombocytopenia · study director
• Ph1
  NCT04185415 · A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)

  UCB Biopharma SRL · completed · Progressive Supranuclear Palsy · study director
• Ph1
  NCT04163016 · A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

  UCB Biopharma SRL · completed · Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease · study director
• Ph1
  NCT04136444 · A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

  UCB Biopharma S.P.R.L. · terminated · Healthy Study Participants, Impaired Hepatic Function · study director
• Ph1
  NCT04131517 · A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants

  UCB Biopharma SRL · terminated · Healthy Female Participants · study director
• Ph1
  NCT04126343 · A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants

  UCB Biopharma S.P.R.L. · terminated · Healthy Study Participants · study director
• Ph3
  NCT04124965 · A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

  UCB Biopharma SRL · completed · Generalized Myasthenia Gravis · study director
• Ph3
  NCT04123795 · A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

  UCB Biopharma SRL · completed · Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis · study director
• Ph3
  NCT04115293 · Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

  Ra Pharmaceuticals, Inc. · completed · Myasthenia Gravis, Generalized · study director
• Ph3
  NCT04109976 · A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

  UCB Biopharma SRL · completed · Psoriatic Arthritis · study director
• Ph1
  NCT04075409 · A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants

  UCB Biopharma S.P.R.L. · completed · Healthy Japanese Participants · study director
• N/A
  NCT04053881 · A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

  UCB Biopharma SRL · completed · Plaque Psoriasis · study director
• Ph2
  NCT04051944 · A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

  UCB Biopharma SRL · completed · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) · study director
• Ph1
  NCT04039919 · A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol

  UCB Biopharma S.P.R.L. · terminated · Healthy Participants · study director
• Ph2
  NCT04025632 · Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

  Ra Pharmaceuticals · terminated · Immune Mediated Necrotizing Myopathy · study director
• Ph1
  NCT04013191 · A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants

  UCB Biopharma S.P.R.L. · completed · Elderly Study Participants, Adult Study Participants · study director
• Ph3
  NCT04009499 · A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

  UCB Biopharma SRL · completed · Psoriatic Arthritis · study director
• Ph3
  NCT03992196 · A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

  UCB Biopharma SRL · terminated · Restless Legs Syndrome · study director
• Ph3
  NCT03971422 · A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

  UCB Biopharma SRL · completed · Generalized Myasthenia Gravis · study director
• Ph3
  NCT03936777 · A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

  Zogenix, Inc. · completed · Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy · study director
• Ph3
  NCT03928704 · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

  UCB Biopharma SRL · completed · Nonradiographic Axial Spondyloarthritis · study director
• Ph3
  NCT03928743 · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

  UCB Biopharma SRL · completed · Ankylosing Spondylitis · study director
• Ph3
  NCT03896581 · A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

  UCB Biopharma SRL · completed · Psoriatic Arthritis · study director
• Ph3
  NCT03895203 · A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

  UCB Biopharma SRL · completed · Psoriatic Arthritis · study director
• Ph1
  NCT03895385 · A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

  UCB Biopharma S.P.R.L. · completed · Healthy Volunteers · study director
• Ph2
  NCT03861481 · A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

  UCB Biopharma S.P.R.L. · completed · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) · study director
• Ph1
  NCT03859219 · A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants

  UCB Biopharma S.P.R.L. · completed · Healthy-volunteers · study director
• Ph2
  NCT03845712 · An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

  UCB BIOSCIENCES, Inc. · completed · Thymidine Kinase 2 Deficiency · study director
• Ph3
  NCT03766685 · A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

  UCB Biopharma SRL · completed · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis · study director
• Ph3
  NCT03739840 · A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

  UCB Biopharma SRL · terminated · Drug-Resistant Epilepsy, Focal-Onset Seizures · study director
• Ph3
  NCT03728933 · A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

  UCB Biopharma SRL · terminated · Restless Legs Syndrome · study director
• Ph1
  NCT03707717 · A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants

  UCB Biopharma S.P.R.L. · completed · Healthy Volunteers · study director
• N/A
  NCT03701568 · A RETROspective Study of Patients With TK2d

  Zogenix MDS, Inc. · completed · Thymidine Kinase 2 (TK2) · study director
• Ph1
  NCT03695094 · A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

  UCB Biopharma S.P.R.L. · completed · Epilepsy · study director
• Ph3
  NCT03685630 · A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

  UCB Biopharma S.P.R.L. · completed · Partial Seizures With or Without Secondary Generalization, Epilepsy · study director
• Ph1
  NCT03605082 · A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese Subjects

  UCB Biopharma S.P.R.L. · completed · Healthy Japanese Volunteers · study director
• Ph3
  NCT03598790 · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

  UCB Biopharma SRL · completed · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis · study director
• N/A
  NCT03559660 · CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)

  UCB Biopharma SRL · no longer available · Crohn's Disease · study director
• N/A
  NCT03559673 · Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures

  UCB Biopharma S.P.R.L. · no longer available · Epilepsies, Partial · study director
• N/A
  NCT03559686 · Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)

  UCB Biopharma SRL · no longer available · Rheumatoid Arthritis · study director
• Ph3
  NCT03536884 · A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

  UCB Biopharma SRL · completed · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis · study director
• N/A
  NCT03532516 · Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy

  UCB Biopharma SRL · no longer available · Epilepsy · study director
• Ph1
  NCT03480243 · Study to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of Padsevonil

  UCB Biopharma S.P.R.L. · completed · Pharmacokinetics · study director
• Ph1
  NCT03464227 · A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects

  UCB Biopharma S.P.R.L. · completed · Healthy Male Volunteers · study director
• Ph3
  NCT03412747 · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

  UCB Biopharma SRL · completed · Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis · study director
• Ph3
  NCT03410992 · A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

  UCB Biopharma SRL · completed · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis · study director
• Ph2
  NCT03405714 · A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy

  UCB Biopharma S.P.R.L. · completed · Epilepsy · study director
• Ph2
  NCT03373383 · Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

  UCB Biopharma S.P.R.L. · completed · Drug-resistant Epilepsy, Focal-Onset Seizures · study director
• Ph2
  NCT03370120 · Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

  UCB Biopharma SRL · terminated · Drug-Resistant Epilepsy, Focal-Onset Seizures · study director
• Ph3
  NCT03370133 · A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

  UCB Biopharma SRL · completed · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis · study director
• Ph3
  NCT03357471 · Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

  UCB Biopharma S.P.R.L. · completed · Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis · study director
• Ph3
  NCT03355209 · A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

  Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. · completed · Lennox Gastaut Syndrome · study director
• Ph2
  NCT03355573 · A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

  UCB Biopharma SRL · completed · Ankylosing Spondylitis · study director
• Ph2
  NCT03347110 · A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

  UCB Biopharma SRL · completed · Psoriatic Arthritis · study director
• Ph3
  NCT03340064 · A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age

  UCB Japan Co. Ltd. · completed · Partial Seizures · study director
• Ph3
  NCT03325439 · A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures

  UCB Biopharma SRL · terminated · Electroencephalographic Neonatal Seizures · study director
• Ph2
  NCT03315130 · Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

  Ra Pharmaceuticals · completed · Generalized Myasthenia Gravis · study director
• Ph3
  NCT03299842 · A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome

  Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. · terminated · Dravet Syndrome · study director
• Ph3
  NCT03250377 · A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

  UCB Biopharma SRL · completed · Partial Seizures With or Without Secondary Generalization, Epilepsy · study director
• Ph2
  NCT03248531 · A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

  UCB Biopharma SRL · completed · Hidradenitis Suppurativa · study director
• Ph2
  NCT03230292 · A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

  UCB Biopharma SRL · completed · Chronic Plaque Psoriasis · study director
• Ph2
  NCT03215277 · A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

  UCB Biopharma SRL · completed · Ankylosing Spondylitis · study director
• Ph1
  NCT03204474 · A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects

  UCB Biopharma S.P.R.L. · completed · Healthy Male Chinese Volunteers · study director
• Ph1
  NCT03168984 · A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects

  UCB Biopharma S.P.R.L. · completed · Healthy Japanese and Caucasian Subjects · study director
• Ph4
  NCT03103919 · Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

  UCB Biopharma S.P.R.L. · completed · Parkinson´s Disease · study director
• Ph1
  NCT03086382 · A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects

  UCB Biopharma S.P.R.L. · completed · Healthy Male Volunteers · study director
• Ph3
  NCT03083665 · A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

  UCB Biopharma SRL · completed · Partial Seizures With or Without Secondary Generalization, Epilepsy · study director
• Ph2
  NCT03052751 · Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

  UCB Biopharma S.P.R.L. · completed · Myasthenia Gravis · study director
• Ph2/Ph3
  NCT03051217 · A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

  UCB Biopharma S.P.R.L. · completed · Moderate to Severe Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis · study director
• Ph2
  NCT03025542 · A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

  UCB Biopharma SRL · completed · Chronic Plaque Psoriasis · study director
• Ph4
  NCT03020992 · A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU

  UCB Biopharma SRL · completed · Axial Spondyloarthritis (axSpA), Anterior Uveitis (AU) · study director
• Ph2
  NCT03021018 · A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

  UCB Biopharma S.P.R.L. · completed · Epilepsy · study director
• Ph2
  NCT03010527 · A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

  UCB Biopharma SRL · completed · Chronic Plaque Psoriasis · study director
• Ph1
  NCT02972125 · A Study to Demonstrate the Bioequivalence of Lacosamide Tablets and Dry Syrup in Healthy Male Japanese Subjects

  UCB Biopharma S.P.R.L. · completed · Healthy Volunteers · study director
• Ph2
  NCT02969525 · A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

  UCB Biopharma S.P.R.L. · completed · Psoriatic Arthritis · study director
• Ph2
  NCT02963506 · A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

  UCB Biopharma S.P.R.L. · completed · Ankylosing Spondylitis · study director
• Ph2
  NCT02905006 · Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

  UCB Biopharma S.P.R.L. · completed · Chronic Plaque Psoriasis · study director
• Ph1
  NCT02879877 · A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers

  UCB Biopharma S.P.R.L. · completed · Healthy Volunteers · study director
• Ph1
  NCT02873767 · A First-In-Human Study With a Single Dose UCB4019 in Healthy Volunteers

  UCB Biopharma S.P.R.L. · completed · Healthy Volunteers · study director
• Ph2
  NCT02829827 · A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

  UCB Biopharma S.P.R.L. · terminated · Infantile Spasms (IS) · study director
• Ph3
  NCT02823145 · An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

  Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. · completed · Dravet Syndrome · study director
• Ph1
  NCT02806219 · Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

  UCB BIOSCIENCES, Inc. · completed · Healthy · study director
• Ph2
  NCT02804763 · A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

  UCB Biopharma S.P.R.L. · completed · Systemic Lupus Erythematosus (SLE) · study director
• N/A
  NCT02775656 · UCB Cimzia Pregnancy Follow-up Study

  UCB BIOSCIENCES, Inc. · terminated · Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA) · study director
• Ph2
  NCT02718716 · Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

  UCB Biopharma SRL · completed · Thrombocytopenia · study director
• Ph2/Ph3
  NCT02710890 · Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.

  UCB BIOSCIENCES, Inc. · completed · Epilepsy · study director
• N/A
  NCT02687711 · Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures

  UCB Biopharma S.P.R.L. · completed · Epilepsy With POS With or Without Secondary Generalization · study director
• Ph3
  NCT02682927 · A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

  Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. · completed · Dravet Syndrome, Seizure Disorder · study director
• Ph1
  NCT02647697 · Study to Evaluate Properties of Radiprodil Given in Oral Solution to Healthy Volunteers

  UCB Biopharma S.P.R.L. · completed · Healthy Volunteers · study director
• Ph2
  NCT02625090 · An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

  UCB Biopharma SRL · terminated · Highly Drug-resistant Focal Epilepsy · study director
• Ph2
  NCT02610543 · UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome

  UCB Celltech · terminated · Primary Sjögren's Syndrome · study director
• Ph1
  NCT02602860 · A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

  UCB Pharma · completed · Healthy Volunteers · study director
• Ph3
  NCT02582866 · A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994

  UCB Biopharma S.P.R.L. · completed · Epilepsy · study director
• Ph3
  NCT02552212 · Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

  UCB BIOSCIENCES GmbH · completed · Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA · study director
• Ph3
  NCT02505542 · Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

  UCB BIOSCIENCES GmbH · completed · Axial Spondyloarthrithis, Ankylosing Spondylitis · study director
• Ph2
  NCT02495844 · A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

  UCB Biopharma S.P.R.L. · completed · Highly Drug-resistant Focal Epilepsy · study director
• Ph3
  NCT02477839 · Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures

  UCB BIOSCIENCES, Inc. · completed · Epilepsy With Partial-onset Seizures · study director
• Ph2
  NCT02430909 · Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

  UCB Celltech · completed · Rheumatoid Arthritis · study director
• Ph3
  NCT02408549 · Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

  UCB BIOSCIENCES, Inc. · completed · Epilepsy · study director
• Ph3
  NCT02408523 · A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

  UCB BIOSCIENCES, Inc. · completed · Epilepsy · study director
• N/A
  NCT02354105 · A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life

  UCB Biopharma S.P.R.L. · completed · Axial Spondyloarthritis · study director
• Ph3
  NCT02346240 · Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

  UCB Biopharma S.P.R.L. · completed · Psoriasis, Plaque Psoriasis · study director
• Ph3
  NCT02326272 · A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

  UCB Biopharma S.P.R.L. · completed · Psoriasis, Plaque Psoriasis · study director
• Ph3
  NCT02326298 · An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

  UCB Biopharma S.P.R.L. · completed · Psoriasis, Plaque Psoriasis · study director
• Ph3
  NCT02319642 · An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044

  UCB Pharma SA · completed · Rheumatoid Arthritis · study director
• Ph1
  NCT02303509 · Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject

  UCB Pharma · completed · Psoriasis · study director
• N/A
  NCT02276053 · Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors

  UCB BIOSCIENCES GmbH · completed · Brain Tumor Related Epilepsy (BTRE) · study director
• Ph1
  NCT02154425 · A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

  UCB BIOSCIENCES, Inc. · completed · Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis · study director
• Ph3
  NCT02151851 · A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis

  UCB Pharma SA, Belgium · completed · Rheumatoid Arthritis · study director
• Ph3
  NCT02124564 · A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

  UCB Japan Co. Ltd. · completed · Epilepsy, Partial-onset Seizures · study director

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.